The value of early second trimester PAPP-A and ADAM12 in screening for pre-eclampsia.
The value of early second trimester PAPP-A and ADAM12 in screening for pre-eclampsia.
OBJECTIVE: To estimate the pre-eclampsia screening performance of PAPP-A (pregnancy-associated plasma protein-A) and ADAM12 (A Disintegrin And Metalloprotease 12) in the early second trimester of pregnancy. METHODS: Stored frozen serum samples from a previously published nested case-control study comprising 77 women who developed pre-eclampsia and 224 unaffected controls were thawed and assayed for PAPP-A and ADAM12. Levels were converted into multiple of the unaffected median (MoM) values. RESULTS: Neither PAPP-A or ADAM12 were significantly different in women who developed pre-eclamspia compared with unaffected controls (PAPP-A: 0.97 MoM [95% confidence interval 0.73 to 1.25], ADAM12: 1.01 MoM [0.91 to 1.13]). CONCLUSION: Our results do not support the use of PAPP-A or ADAM12 in early second trimester antenatal screening for pre-eclampsia.
Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ.
Previous Document: Schizophrenia patients with a history of childhood trauma have a pro-inflammatory phenotype.
Next Document: Adding ductus venosus blood flow as a categorical variable to the Combined and Integrated tests in D...
